Adaptive Biotechnologies (ADPT) News Today $6.81 -0.11 (-1.59%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 17.6% - Time to Buy?Adaptive Biotechnologies (NASDAQ:ADPT) Trading Up 17.6% - Here's WhyJanuary 15, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.5% - What's Next?Adaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.5% - What's Next?January 14, 2025 | marketbeat.comAdaptive Biotechnologies and NeoGenomics Partner to Expand Access to Personalized Disease Monitoring for Blood Cancer PatientsJanuary 14, 2025 | globenewswire.comBarclays PLC Boosts Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Barclays PLC lifted its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 149.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 230,177 shares of the company'sJanuary 14, 2025 | marketbeat.comCathie Wood's Ark Invest Loads Up On Intellia Therapeutics Which Laid Off Over A Quarter Of Its WorkforceJanuary 11, 2025 | benzinga.comAdaptive Biotechnologies announces lab fee schedule rate of $2,007 for clonoSEQJanuary 9, 2025 | markets.businessinsider.comAdaptive Biotechnologies Announces Clinical Lab Fee Schedule Rate of $2,007 for clonoSEQ® Test for Minimal Residual Disease Assessment is Effective as of January 1st, 2025January 7, 2025 | globenewswire.comAdaptive Biotechnologies (NASDAQ:ADPT) Sees Strong Trading Volume - What's Next?Adaptive Biotechnologies (NASDAQ:ADPT) Sees Large Volume Increase - Here's WhyJanuary 6, 2025 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Sets New 1-Year High - Still a Buy?Adaptive Biotechnologies (NASDAQ:ADPT) Sets New 12-Month High - Here's What HappenedJanuary 3, 2025 | marketbeat.comAnalysts Offer Insights on Healthcare Companies: Adaptive Biotechnologies (ADPT) and Teladoc (TDOC)January 3, 2025 | markets.businessinsider.comAdaptive Biotechnologies to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2025 | globenewswire.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Up 7.3% - What's Next?Adaptive Biotechnologies (NASDAQ:ADPT) Shares Up 7.3% - Should You Buy?January 2, 2025 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Significant Drop in Short InterestAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) was the recipient of a large decrease in short interest in the month of December. As of December 15th, there was short interest totalling 9,030,000 shares, a decrease of 5.7% from the November 30th total of 9,580,000 shares. Based on an average daily trading volume, of 1,240,000 shares, the days-to-cover ratio is presently 7.3 days.December 31, 2024 | marketbeat.comBarclays PLC Has $1.18 Million Stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Barclays PLC boosted its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 149.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 230,177 shares of the company's stockDecember 30, 2024 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Jane Street Group LLCJane Street Group LLC lessened its stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 50.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 504,277 shares of the company's stock after selling 517,256 shares during the quDecember 23, 2024 | marketbeat.comAdaptive Biotechnologies Gains Positive Outlook with Strategic Advancements and Increased clonoSEQ UtilizationDecember 19, 2024 | markets.businessinsider.comAdaptive Biotechnologies price target raised to $9 from $8 at BTIGDecember 19, 2024 | markets.businessinsider.comAdaptive Biotechnologies (NASDAQ:ADPT) Stock Price Down 6.6% - What's Next?Adaptive Biotechnologies (NASDAQ:ADPT) Trading Down 6.6% - Here's WhyDecember 18, 2024 | marketbeat.comBTIG Research Issues Positive Forecast for Adaptive Biotechnologies (NASDAQ:ADPT) Stock PriceBTIG Research lifted their price objective on Adaptive Biotechnologies from $8.00 to $9.00 and gave the company a "buy" rating in a report on Wednesday.December 18, 2024 | marketbeat.comFmr LLC Grows Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Fmr LLC raised its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 102.0% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 233,566 shares of the company's stock after acquiring an additional 117,965 shares during the qDecember 17, 2024 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Large Growth in Short InterestAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) was the target of a significant increase in short interest in November. As of November 30th, there was short interest totalling 9,580,000 shares, an increase of 16.8% from the November 15th total of 8,200,000 shares. Based on an average trading volume of 1,190,000 shares, the short-interest ratio is presently 8.1 days.December 14, 2024 | marketbeat.com495,492 Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Bought by Point72 Asset Management L.P.Point72 Asset Management L.P. bought a new stake in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 495,492 shares of the coDecember 10, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Purchases New Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Jacobs Levy Equity Management Inc. acquired a new position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 143,679 shares of the compDecember 10, 2024 | marketbeat.comPier Capital LLC Grows Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Pier Capital LLC lifted its stake in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 20.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,275,885 shares of the company's stock after buying an additionalDecember 8, 2024 | marketbeat.comAdaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment DecisionsDecember 7, 2024 | globenewswire.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Sold by Matrix Capital Management Company LPMatrix Capital Management Company LP lessened its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 94.4% during the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 650,000 shares of the company's stock after selling 10,922,590 shareDecember 4, 2024 | marketbeat.comAdaptive Biotechnologies Announces Over 65 Abstracts Featuring clonoSEQ® MRD Testing Across a Range of Blood Cancers to be Presented at the 66th ASH Annual MeetingDecember 3, 2024 | globenewswire.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Sees Large Decline in Short InterestAdaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) was the target of a large drop in short interest in the month of November. As of November 15th, there was short interest totalling 8,200,000 shares, a drop of 8.5% from the October 31st total of 8,960,000 shares. Based on an average daily trading volume, of 1,140,000 shares, the short-interest ratio is presently 7.2 days.December 2, 2024 | marketbeat.comCerity Partners LLC Purchases 256,933 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)Cerity Partners LLC raised its position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 58.7% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 694,417 shares of the company's stock after buyinNovember 30, 2024 | marketbeat.comAdaptive Biotechnologies Co. (NASDAQ:ADPT) Shares Purchased by Rubric Capital Management LPRubric Capital Management LP grew its holdings in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 2.9% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 14,400,000 shares of the company's stock after buying an aNovember 27, 2024 | marketbeat.comMassachusetts Financial Services Co. MA Lowers Stock Position in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Massachusetts Financial Services Co. MA reduced its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 26.3% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,881,36November 27, 2024 | marketbeat.comAdaptive Biotechnologies: Making Some ProgressNovember 26, 2024 | seekingalpha.comMillrace Asset Group Inc. Acquires New Shares in Adaptive Biotechnologies Co. (NASDAQ:ADPT)Millrace Asset Group Inc. acquired a new position in Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 272,681 shares of the company's stock, valued at approximately $1,396,November 26, 2024 | marketbeat.comBalanced Hold Recommendation for Adaptive Biotechnologies Amid Positive Performance and External ChallengesNovember 19, 2024 | markets.businessinsider.comWhat is William Blair's Estimate for ADPT FY2024 Earnings?Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) - Stock analysts at William Blair boosted their FY2024 EPS estimates for shares of Adaptive Biotechnologies in a report released on Thursday, November 14th. William Blair analyst A. Brackmann now anticipates that the company will post earniNovember 18, 2024 | marketbeat.comShort Interest in Adaptive Biotechnologies Co. (NASDAQ:ADPT) Declines By 5.5%Adaptive Biotechnologies Co. (NASDAQ:ADPT - Get Free Report) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 8,960,000 shares, a decrease of 5.5% from the October 15th total of 9,480,000 shares. Based on an average daily volume of 1,050,000 shares, the short-interest ratio is presently 8.5 days.November 18, 2024 | marketbeat.comSumitomo Mitsui Trust Group Inc. Acquires 834,253 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)Sumitomo Mitsui Trust Group Inc. lifted its holdings in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 12.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,733,884 shares of the company's sNovember 16, 2024 | marketbeat.comAdaptive Biotechnologies (ADPT) Receives a Buy from ScotiabankNovember 13, 2024 | markets.businessinsider.comAdaptive Biotechnologies price target raised to $7 from $6 at Piper SandlerNovember 11, 2024 | markets.businessinsider.comJ.P. Morgan Remains a Buy on Adaptive Biotechnologies (ADPT)November 11, 2024 | markets.businessinsider.comAdaptive Biotechnologies (NASDAQ:ADPT) Trading 12.7% Higher After Analyst UpgradeAdaptive Biotechnologies (NASDAQ:ADPT) Trading 12.7% Higher Following Analyst UpgradeNovember 11, 2024 | marketbeat.comAdaptive Biotechnologies (NASDAQ:ADPT) Price Target Raised to $7.00Piper Sandler increased their price objective on shares of Adaptive Biotechnologies from $6.00 to $7.00 and gave the company an "overweight" rating in a research report on Monday.November 11, 2024 | marketbeat.comAdaptive Biotechnologies’ Q3 2024 Financial Performance OverviewNovember 9, 2024 | markets.businessinsider.comAdaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up Following Better-Than-Expected EarningsAdaptive Biotechnologies (NASDAQ:ADPT) Shares Gap Up on Earnings BeatNovember 8, 2024 | marketbeat.comAdaptive Biotechnologies sees FY MRD business revenue $143 M-$145MNovember 8, 2024 | markets.businessinsider.comTD Cowen Reaffirms Their Buy Rating on Adaptive Biotechnologies (ADPT)November 8, 2024 | markets.businessinsider.comARK Investment Management LLC Purchases 189,134 Shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT)ARK Investment Management LLC lifted its position in shares of Adaptive Biotechnologies Co. (NASDAQ:ADPT - Free Report) by 1.7% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 11,601,134 shares ofNovember 8, 2024 | marketbeat.comAdaptive Biotechnologies Q3 Loss Decreases, Beats EstimatesNovember 8, 2024 | markets.businessinsider.comAdaptive Biotechnologies Reports Third Quarter 2024 Financial ResultsNovember 8, 2024 | markets.businessinsider.comAdaptive Biotechnologies Corp (ADPT) Q3 2024 Earnings Call Highlights: Strong MRD Growth Amidst ...November 8, 2024 | finance.yahoo.com Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address ADPT Media Mentions By Week ADPT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ADPT News Sentiment▼0.540.44▲Average Medical News Sentiment ADPT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ADPT Articles This Week▼44▲ADPT Articles Average Week Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alvotech News Today Biohaven News Today ADMA Biologics News Today Apellis Pharmaceuticals News Today Ultragenyx Pharmaceutical News Today Viking Therapeutics News Today Arcellx News Today Immunovant News Today Crinetics Pharmaceuticals News Today Avidity Biosciences News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ADPT) was last updated on 1/20/2025 by MarketBeat.com Staff From Our PartnersBill Gates’ is about to mint millionaires (again) with Stargate.This little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTop Picks for Trump’s Pro-Crypto AmericaThe Crypto ETF Windfall: 27 Experts Tell All (Free) Don't miss your chance to see exactly what crypto's eli...Crypto 101 Media | SponsoredWarren Buffett Bets $40 Billion—You Can Get in for $20I call it "The Last Retirement Stock You'll Ever Need." Warren Buffett himself owns $40 billion of stock in...Behind the Markets | SponsoredKamala’s final humiliation The investments connected to Trump's second term in ways that almost nobody outside his inner circle is aware ...Porter & Company | SponsoredNvidia’s Bold Move: Tackling Tech’s $1 Trillion CrisisTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredTrump’s Inauguration Shocker: “Move Your Cash Now”Just in the first week after Trump's win, many stocks jumped by double and even triple digits. But now he's...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ADPT Stock Alerts